The study focuses on preemptive immunomodulation strategies to reduce relapse rates in Acute Myeloid Leukemia (AML) patients post-allogeneic stem cell transplantation (Allo-HSCT). Given that relapses account for approximately 30% of mortality in this patient population, successful outcomes could position the University Hospital, Caen, as a leader in innovative transplant protocols. The findings may influence treatment guidelines and could lead to partnerships with pharmaceutical companies interested in developing supportive therapies or immunomodulatory agents. The market for AML treatments is competitive, with several established therapies; however, a successful demonstration of reduced relapse rates could enhance the value proposition of Allo-HSCT and related immunomodulatory approaches.